Why the study?
Guidelines recommend targeting preventive interventions toward older adults whose life expectancy exceeds the intervention's time to benefit, but the time to benefit for statin therapy is unknown.
Does statin therapy prevent a first MACE in adults aged 50 to 75 years without known cardiovascular disease?
Does statin therapy prevent a first MACE in adults aged 50 to 75 years without known cardiovascular disease?
In adults aged 50 to 75 years without known cardiovascular disease, statin therapy requires approximately 2.5 years to prevent 1 MACE per 100 patients treated, suggesting treatment should be targeted to those with a life expectancy of at least 2.5 years.
No takes yet. Share an insight, caveat, or question.
Target statin primary prevention to adults with ≥2.5-year life expectancy; extends time-to-benefit estimates for individualized decisions in ages 50-75.
Yourman et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: